Neurocrine Bioscienc (NBIX) 48.46 $NBIX
Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA(TM) for VMAT2 Inhibitor Valbenazine
PR Newswire - Wed Aug 31, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name "INGREZZA(TM)" for the Company's once-daily vesicular monoamine transporter 2 (VMAT2) inhibitor valbenazine. The Company has recently announced the submission of a New Drug Application (NDA) with the FDA for valbenazine in tardive dyskinesia and is also exploring its utility in Tourette syndrome.
NBIX: 48.46 (-0.71)
Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia
PR Newswire - Mon Aug 29, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-daily dosing of valbenazine in treating tardive dyskinesia.
NBIX: 48.46 (-0.71)
SmarTrend Watching for Potential Pullback in Shares of Neurocrine Biosciences After 3.31% Gain
Comtex SmarTrend(R) - Mon Aug 22, 3:48PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $48.75 to a high of $50.28. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $48.61 on volume of 331,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Reports Second Quarter 2016 Results
PR Newswire - Wed Aug 03, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2016. For the second quarter of 2016, the Company reported a net loss of $40.3 million, or $0.46 loss per share, compared to a net loss of $24.0 million, or $0.28 loss per share, for the same period in 2015. For the six months ended June 30, 2016, the Company reported a net loss of $59.5 million, or $0.69 loss per share, as compared to a net loss of $25.2 million, or $0.30 loss per share, for the first half of last year.
NBIX: 48.46 (-0.71)
Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome
PR Newswire - Thu Jul 28, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase II clinical trial for NBI-98854 (valbenazine), a highly selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in children, adolescents and adults with Tourette syndrome.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results
PR Newswire - Wed Jul 27, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2016 results after the Nasdaq market closes on Wednesday, August 3, 2016. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, August 3, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 48.46 (-0.71)
Notable Thursday Option Activity: NBIX, RAD, SEAS
DividendChannel.com - Thu Jun 23, 2:29PM CDT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Neurocrine Biosciences, Inc. , where a total of 4,984 contracts have traded so far, representing approximately 498,400 underlying shares.
NBIX: 48.46 (-0.71)
Watch for Neurocrine Biosciences to Potentially Rebound After Falling 4.83% Yesterday
Comtex SmarTrend(R) - Tue Jun 21, 3:42PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $41.70 to a high of $44.86. Yesterday, the shares fell 4.8%, which took the trading range below the 3-day low of $44.04 on volume of 786,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 2:45PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 Healthcare Conference in New York City.
NBIX: 48.46 (-0.71)
nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman
GlobeNewswire - Wed Jun 01, 4:11AM CDT
nLife Therapeutics, an early-stage biopharmaceutical company leading developments in conjugated nucleic acids as therapeutic agents for central nervous system (CNS) and neuromuscular (NS) disorders, today announced the appointment of Dr. Errol B. De Souza, Ph.D. as executive chairman.
NBIX: 48.46 (-0.71), TRGT: 0.96 (-1.25), CBIO: 1.20 (-0.06), PTN: 0.51 (+0.01), IDXX: 112.68 (-0.38), BIOD: 0.43 (-0.01)
Neurocrine Biosciences Rises 8.70% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 2:08PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $48.49 to a high of $50.87. Yesterday, the shares gained 8.7%, which took the trading range above the 3-day high of $49.44 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Falls 3.33% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu May 26, 2:35PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $44.41 to a high of $46.47. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $46.01 on volume of 513,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors
PR Newswire - Fri May 20, 8:00AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of Directors effective just prior to the 2016 Annual Meeting of Shareholders. Mr. Mitchell has been a member of the Board of Directors for over thirteen years serving in various capacities on the audit, compensation, and nominating and corporate governance committees.
NBIX: 48.46 (-0.71)
After Yesterday's Rally of 4.19% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 16, 4:19PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $43.79 to a high of $46.11. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $44.60 on volume of 434,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Fri May 06, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association's 2016 Annual Meeting in Atlanta
PR Newswire - Fri May 06, 7:30AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatric Association Annual Meeting in May. The four posters will include an evaluation of the impact of valbenazine on the psychiatric stability of subjects with underlying schizophrenia, schizoaffective disorder or mood disorder (including bipolar disorder or major depressive disorder), data assessing the effect of valbenazine stratified by baseline tardive dyskinesia severity, and an evaluation of valbenazine with concomitant antipsychotic use. The APA Annual Meeting is the largest international conference of psychiatrists and behavioral health specialists, bringing together an estimated 13,000 clinicians and scientists to address current topics in psychiatry.
NBIX: 48.46 (-0.71)
Neurocrine reports 1Q loss
Automated Insights - Thu May 05, 5:22PM CDT
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Thursday reported a loss of $19.3 million in its first quarter.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Reports First Quarter 2016 Results
PR Newswire - Thu May 05, 3:01PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2016. For the first quarter of 2016, the Company reported a net loss of $19.3 million, or $0.22 loss per share, compared to a net loss of $1.2 million, or $0.01 loss per share, for the same period in 2015.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results
PR Newswire - Fri Apr 29, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2016 results after the Nasdaq market closes on Thursday, May 5, 2016. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, May 5, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 48.46 (-0.71)
Neurocrine Biosciences to Present at the Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Wed Apr 27, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Deutsche Bank 41st Annual Health Care Conference in Boston.
NBIX: 48.46 (-0.71), DB: 14.75 (+0.36)
Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA(TM) for VMAT2 Inhibitor Valbenazine
PR Newswire - Wed Aug 31, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name "INGREZZA(TM)" for the Company's once-daily vesicular monoamine transporter 2 (VMAT2) inhibitor valbenazine. The Company has recently announced the submission of a New Drug Application (NDA) with the FDA for valbenazine in tardive dyskinesia and is also exploring its utility in Tourette syndrome.
NBIX: 48.46 (-0.71)
Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia
PR Newswire - Mon Aug 29, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-daily dosing of valbenazine in treating tardive dyskinesia.
NBIX: 48.46 (-0.71)
SmarTrend Watching for Potential Pullback in Shares of Neurocrine Biosciences After 3.31% Gain
Comtex SmarTrend(R) - Mon Aug 22, 3:48PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $48.75 to a high of $50.28. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $48.61 on volume of 331,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Reports Second Quarter 2016 Results
PR Newswire - Wed Aug 03, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2016. For the second quarter of 2016, the Company reported a net loss of $40.3 million, or $0.46 loss per share, compared to a net loss of $24.0 million, or $0.28 loss per share, for the same period in 2015. For the six months ended June 30, 2016, the Company reported a net loss of $59.5 million, or $0.69 loss per share, as compared to a net loss of $25.2 million, or $0.30 loss per share, for the first half of last year.
NBIX: 48.46 (-0.71)
Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome
PR Newswire - Thu Jul 28, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase II clinical trial for NBI-98854 (valbenazine), a highly selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in children, adolescents and adults with Tourette syndrome.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results
PR Newswire - Wed Jul 27, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2016 results after the Nasdaq market closes on Wednesday, August 3, 2016. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, August 3, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 48.46 (-0.71)
Notable Thursday Option Activity: NBIX, RAD, SEAS
DividendChannel.com - Thu Jun 23, 2:29PM CDT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Neurocrine Biosciences, Inc. , where a total of 4,984 contracts have traded so far, representing approximately 498,400 underlying shares.
NBIX: 48.46 (-0.71)
Watch for Neurocrine Biosciences to Potentially Rebound After Falling 4.83% Yesterday
Comtex SmarTrend(R) - Tue Jun 21, 3:42PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $41.70 to a high of $44.86. Yesterday, the shares fell 4.8%, which took the trading range below the 3-day low of $44.04 on volume of 786,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 2:45PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 Healthcare Conference in New York City.
NBIX: 48.46 (-0.71)
nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman
GlobeNewswire - Wed Jun 01, 4:11AM CDT
nLife Therapeutics, an early-stage biopharmaceutical company leading developments in conjugated nucleic acids as therapeutic agents for central nervous system (CNS) and neuromuscular (NS) disorders, today announced the appointment of Dr. Errol B. De Souza, Ph.D. as executive chairman.
NBIX: 48.46 (-0.71), TRGT: 0.96 (-1.25), CBIO: 1.20 (-0.06), PTN: 0.51 (+0.01), IDXX: 112.68 (-0.38), BIOD: 0.43 (-0.01)
Neurocrine Biosciences Rises 8.70% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 2:08PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $48.49 to a high of $50.87. Yesterday, the shares gained 8.7%, which took the trading range above the 3-day high of $49.44 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Falls 3.33% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu May 26, 2:35PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $44.41 to a high of $46.47. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $46.01 on volume of 513,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors
PR Newswire - Fri May 20, 8:00AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of Directors effective just prior to the 2016 Annual Meeting of Shareholders. Mr. Mitchell has been a member of the Board of Directors for over thirteen years serving in various capacities on the audit, compensation, and nominating and corporate governance committees.
NBIX: 48.46 (-0.71)
After Yesterday's Rally of 4.19% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon May 16, 4:19PM CDT
Neurocrine Biosciences (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $43.79 to a high of $46.11. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $44.60 on volume of 434,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Fri May 06, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association's 2016 Annual Meeting in Atlanta
PR Newswire - Fri May 06, 7:30AM CDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatric Association Annual Meeting in May. The four posters will include an evaluation of the impact of valbenazine on the psychiatric stability of subjects with underlying schizophrenia, schizoaffective disorder or mood disorder (including bipolar disorder or major depressive disorder), data assessing the effect of valbenazine stratified by baseline tardive dyskinesia severity, and an evaluation of valbenazine with concomitant antipsychotic use. The APA Annual Meeting is the largest international conference of psychiatrists and behavioral health specialists, bringing together an estimated 13,000 clinicians and scientists to address current topics in psychiatry.
NBIX: 48.46 (-0.71)
Neurocrine reports 1Q loss
Automated Insights - Thu May 05, 5:22PM CDT
SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Thursday reported a loss of $19.3 million in its first quarter.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Reports First Quarter 2016 Results
PR Newswire - Thu May 05, 3:01PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2016. For the first quarter of 2016, the Company reported a net loss of $19.3 million, or $0.22 loss per share, compared to a net loss of $1.2 million, or $0.01 loss per share, for the same period in 2015.
NBIX: 48.46 (-0.71)
Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results
PR Newswire - Fri Apr 29, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2016 results after the Nasdaq market closes on Thursday, May 5, 2016. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, May 5, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
NBIX: 48.46 (-0.71)
Neurocrine Biosciences to Present at the Deutsche Bank 41st Annual Health Care Conference
PR Newswire - Wed Apr 27, 2:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Deutsche Bank 41st Annual Health Care Conference in Boston.
NBIX: 48.46 (-0.71), DB: 14.75 (+0.36)
